DCF Valuation Model for Invex Therapeutics, page-81

If I understand your DCF model correctly you have only looked at IIH in women ?

If I am correct in that assumption, I think it would be more than reasonable to add in the incidence in the male population. Although this is not a large absolute or relative number the resultant impact would be well above the margin of error.

As I understand it most men who are diagnosed with IIH first present with vision problem and as such they are in need of immediate intervention. It might be something to explore with Tom or Alex Sinclair, but I would expect you would see a much higher percentage of the men who are newly diagnosed put on to immidiate treatment than you would with the female cohort.